Beyond the Guidelines: Treatment of Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis

被引:2
|
作者
Tompkins, Madeline G. [1 ]
Pettit, Rebecca [1 ]
机构
[1] Indiana Univ Hlth, Riley Hosp Children, Indianapolis, IN USA
关键词
cystic fibrosis; corticosteroids; pulmonary; antifungals; biopharmaceutics; ANTI-IGE ANTIBODY; OMALIZUMAB TREATMENT; THERAPY; POSACONAZOLE; PATIENT; ABPA; BENRALIZUMAB; AMPHOTERICIN; MANAGEMENT; CHILDREN;
D O I
10.1177/10600280211022065
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To review the available literature addressing alternative allergic bronchopulmonary aspergillosis (ABPA) treatment options for patients with cystic fibrosis (CF). Data Sources: A literature search of PubMed was performed (January 2002 to April 2021) using the following search terms: allergic bronchopulmonary aspergillosis, aspergillus-related lung disease, cystic fibrosis. Manufacturer prescribing information, clinical practice guidelines, and data from ClinicalTrials.gov were incorporated in the reviewed data. Study Selection and Data Extraction: Relevant English-language studies or those conducted in humans were considered for inclusion. Data Synthesis: Available literature for alternative ABPA treatments in CF is lacking randomized controlled trials, but there is considerable support in case reports and case series describing the benefits in pediatric and adult patients. Recent literature has begun to explore the place in therapy for novel, corticosteroid-sparing treatment approaches. The alternative therapies summarized in this review all resulted in clinical improvement and subsequent discontinuation or dose reductions of oral corticosteroids, with minimal reported adverse drug effects. Relevance to Patient Care and Clinical Practice: Although corticosteroids are the cornerstone of ABPA management, the toxicities can be significant limitations in an already high-risk patient population. Patients may fail or become intolerant to guideline-recommended therapies and require alternative treatment approaches. Conclusions: Alternative treatment modalities for ABPA in patients with CF, including azole antifungals, pulsed intravenous glucocorticoids, omalizumab, mepolizumab, and inhaled amphotericin, appear to be efficacious and well tolerated. Pharmacological properties including route of administration, storage and stability, beyond use dating, and adverse effects of the various treatment modalities must be considered when selecting a practical care plan for patients.
引用
收藏
页码:181 / 192
页数:12
相关论文
共 50 条
  • [31] Aerosolized Amphotericin for the Treatment of Allergic Bronchopulmonary Aspergillosis
    Hayes, Don, Jr.
    Murphy, Brian S.
    Lynch, James E.
    Feola, David J.
    PEDIATRIC PULMONOLOGY, 2010, 45 (11) : 1145 - 1148
  • [32] Allergic bronchopulmonary aspergillosis (ABPA) in patients with cystic fibrosis (CF). Clinical importance, diagnosis and treatment
    Paul, KD
    Leupold, W
    BlaschkeHellmessen, R
    Ulbrich, K
    PeterKern, M
    Neumeister, V
    MYCOSES, 1996, 39 : 55 - 58
  • [33] Allergic bronchopulmonary aspergillosis
    Tillie-Leblond, I.
    le Rouzic, O.
    Cortot, A.
    REVUE FRANCAISE D ALLERGOLOGIE, 2012, 52 (03): : 134 - 137
  • [34] Treating Allergic Bronchopulmonary Aspergillosis with Short-Term Prednisone and Itraconazole in Cystic Fibrosis
    Gothe, Florian
    Schmautz, Alessa
    Haeusler, Kurt
    Nguyen-Binh Tran
    Kappler, Matthias
    Griese, Matthias
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2020, 8 (08) : 2608 - +
  • [35] Chemokines indicate allergic bronchopulmonary aspergillosis in patients with cystic fibrosis
    Hartl, Dominik
    Latzin, Philipp
    Zissel, Gernot
    Krane, Markus
    Krauss-Etschmann, Susanne
    Griese, Matthias
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2006, 173 (12) : 1370 - 1376
  • [36] Comparison of serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis
    Latzin, P.
    Hartl, D.
    Regamey, N.
    Frey, U.
    Schoeni, M. H.
    Casaulta, C.
    EUROPEAN RESPIRATORY JOURNAL, 2008, 31 (01) : 36 - 42
  • [37] Omalizumab for asthma and allergic bronchopulmonary aspergillosis in adults with cystic fibrosis
    Koutsokera, Angela
    Corriveau, Sophie
    Sykes, Jenna
    Coriati, Adele
    Cortes, Daniel
    Vadas, Peter
    Chaparro, Cecilia
    McIntyre, Kieran
    Tullis, Elizabeth
    Stephenson, Anne L.
    JOURNAL OF CYSTIC FIBROSIS, 2020, 19 (01) : 119 - 124
  • [38] Bronchocele density in cystic fibrosis as an indicator of allergic bronchopulmonary aspergillosis: A preliminary study
    Occelli, Aurelie
    Soize, Sebastien
    Ranc, Caroline
    Giovannini-Chami, Lisa
    Bailly, Carole
    Leloutre, Beatrice
    Boyer, Corinne
    Baque-Juston, Marie
    EUROPEAN JOURNAL OF RADIOLOGY, 2017, 93 : 195 - 199
  • [39] Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis
    Jat, Kana R.
    Walia, Dinesh K.
    Khairwa, Anju
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (11):
  • [40] Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis
    Jat, Kana R.
    Walia, Dinesh K.
    Khairwa, Anju
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (03):